Accurate mitochondrial DNA (mtDNA) variant annotation is essential for the clinical diagnosis of diverse human diseases. Substantial challenges to this process include the inconsistency in mtDNA nomenclatures, the existence of multiple reference genomes, and a lack of reference population frequency data. Clinicians need a simple bioinformatics tool that is user-friendly, and bioinformaticians need a powerful informatics resource for programmatic usage. Here, we report
various genomic resources and technologies including design and manifest files, commercial analysis software, and custom sequence analysis pipelines. The first mtDNA reference genome was the Cambridge Reference Sequence (CRS) (Anderson et al., 1981) , derived from Sanger sequencing of the mtDNA genome of a Caucasian individual who belonged to the H haplogroup; this sequence represents one end branch of the phylogenetic tree but has been shown to contain sequencing errors. The Revised Cambridge Reference Sequence (rCRS, NCBI Reference Sequence Acc#: NC_012920.1, 16,569 bp in length) was introduced to correct those errors (Andrews et al., 1999) and added one artificial spacer at position 3,107 to preserve the historical CRS position numbering. This rCRS is the most commonly used reference genome for human mtDNA research. However, earlier releases of the GRCh37 human reference genome and, as a result the UCSC hg19 genome release, used the full mtDNA genome sequence of an African individual as the mtDNA reference genome YRI (NCBI Reference Sequence Acc#: NC_001807.4, Yoruban, L3e haplogroup, 16,571 bp in length), which has different position numbering due to the genome length difference and over 40 differences from rCRS.
Although the error was fixed in later releases of GRCh37, as well as the newest GRCh38 human genome build, it has been used by major genotyping companies including Affymetrix and Illumina in various genomics platforms (e.g., Affymetrix Genome-Wide Human SNP Array 6.0; Illumina 550 v.1, 550 v.3, 610 v.1). The popularity of these genotyping platforms has led to discordant nucleotide numbers and alleles in variant calling from those based on the rCRS sequence.
The same problem has occurred with many academic pipelines that rely upon UCSC hg19 reference genome. Adding to the complexity has been the proposition and use of yet another mtDNA reference genome, revised sapient reference sequence (RSRS), which was an inferred mtDNA sequence falling between haplogroups L0 and L1 ′ 2 ′ 3 ′ 4 ′ 5 ′ 6 evolutionally intended to represent the root mtDNA genome sequence for better rooting of phylogenetic trees (Behar et al., 2012) . RSRS is 16,569 bp in length, including three spacers (positions 523, 524, and 3,107) to preserve the historical CRS position numbering. Overall, the literature is filled with mtDNA variants called based on different reference sequences that have led to widespread confusion and mistakes. These problems need to be resolved to avoid further error propagation. A third major barrier to mtDNA genome analysis is the lack of comprehensive and up-to-date mtDNA pathogenic variant databases. Most mtDNA Web resources are either limited in data scope or not updated for years. Database exceptions include MitoMap (Lott et al., 2013 ; https://www.mitomap.org], HmtDB (Clima et al., 2016 ; https://www.hmtdb.uniba.it/hmdb/), and MSeqDR (Falk et al., 2015; Shen et al., 2016 ; https://mseqdr.org). Finally, a fourth barrier to mtDNA analysis is the paucity of mtDNA variants reported in large sequencing projects, established bioinformatics pipelines, and resources. This results in a significant lack of mtDNA variant population frequency data despite the ease to obtain and analyze mtDNA sequence data in large sequencing projects, including the absence of mtDNA data from most widely used reference database such as ExAC and its expanded successor gnoMAD (Lek et al., 2016) is much desired to facilitate these analyses for clinical purposes, bioinformaticians would benefit from access to convenient, powerful Web services for batch processing a large number of mtDNA variants in an automated way from the command line and programmatically. Indeed, whole-exome sequencing or whole-genome sequencing data usually contain sufficient reads from mtDNA genome to allow for mtDNA variant analysis in association with various human diseases almost as byproducts but rarely utilized and could be fruitful to mine by bioinformaticians across a wide breadth of clinical and research projects.
To overcome these challenges of mtDNA genomics, we estab- 
METHODS

mvTool chromosome and variant converter module
The main mvTool feature for nonbioinformaticians is its user-friendly support of accepting flexible variant input formats. As discussed above, many mtDNA variant nomenclatures remain in use. mvTool can support all input formats, whether separately or combined (Table 1) .
Mitochondrial chromosome names currently used include "M," "MT," "ChrM," "ChrMT," and "NC_01290. 
mvTool variant annotation module
Once mtDNA variant formats are converted and standardized, they can be annotated in the mvTool annotation module. The mvTool annotation module shares much of the backend data with the MSeqDR VariantOneStop and HBCR annotation tools, which are also useful for annotation of nuclear DNA variants (Falk et al., 2015; Shen et al., 2016) . mvTool annotation module individually iterates through the list of input variants of potentially mixed input formats. For a variant that has not been annotated previously by any MSeqDR user, mvTool conducts new prediction by calling Ensembl VEP RESTful API, and stores its genomic annotations in an internal database that mvTool will search first. For previously annotated variants, mvTool simply extracts and returns these existing annotations, but with updated population and pathogenicity data from the MSeqDR Consortium members (Falk et al., 2015; Shen et al., 2016 Python, bash, and perl scripting are also used at the back-end. 
RESULTS
Running mvTool
Output
Variant annotations provided by mvTool consist of six categories: (1)
MSeqDR community population allele frequency, (2) diseases and phenotypes, (3) general annotations, (4) dbNSFP (Liu, Jian, & Boerwinkle, 2013) and CADD scores (Kircher et al., 2014) , (5) HmtDB pathogenicity predictions, and (6) somatic variant data from the International Cancer Genome Consortium (ICGC) (Zhang et al., 2011) and the Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2016) .
In category 1, the population allele frequency of each variant is provided, based on resources and populations listed in Table 2 . In category 2, reported associations with diseases and phenotypes of each variant is provided, based on data obtained from MSeqDR locus-specific database (LSDB), ClinVar, HmtDB, and literature curated by MitoMap.
In category 3, genomic annotations are provided by VEP for each variant, namely the affected gene, transcript and codon all defined in HGVS nomenclature, as well as SIFT and PolyPhen predictions. In category 4, more comprehensive genomic annotations are provided based on dbNSFP, including the CADD scores but limited to the coding region for protein variants. In category 5, the predicted pathogenicity of each possible coding or non-coding variant, whether prior reported or not, is provided by HmtDB (Clima et al., 2016 
CONCLUSIONS
We have developed a powerful Web service for standardized mtDNA variant annotations that are comprehensive and incorporate userfriendly input and output format options. The mvTool API generates VCF and JSON output formats to facilitate the ready integration of mvTool into other sequence analysis pipelines. mvTool harnesses actively updated mtDNA annotations from highly-recognized and widely used mitochondrial genome curation and analysis resources, namely MitoMap, HmtDB, and MSeqDR. These resources collectively offer the largest collection of reference mtDNA genomes and variant data sets. mvTool complements the MSeqDR Phy-mer (NavarroGomez et al., 2014) and MToolBox resources that work on sequence data in FASTQ, BAM, and classical FASTA formats. Together, these resources provide a full dynamic range of mtDNA genomic data analyses and processing capability in the unified MSeqDR Website (https://mseqdr.org/). We welcome suggestions from users on this mvTool and the MSeqDR resource in general (https://mseqdr.org/feedback.php).
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